Sugi Predict

Sugi Predict / Compounds / SCHEMBL23975119

SCHEMBL23975119

SCHEMBL23975119

COc1ccc(C2N(c3ccccc3)C(=O)C2(F)F)cc1

nearest known ligand 0.70

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.70
▸ SMN1; SMN2 Q16637 2/20 0.66
▸ MEN1 O00255 1/20 0.66
▸ MAPT P10636 1/20 0.66
▸ KMT2A Q03164 1/20 0.66
▸ MCOLN3 Q8TDD5 1/20 0.66
▸ HSD11B1 P28845 12/20 0.64
▸ SOAT1 P35610 2/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8103610 0.78 HSD11B1 (1.00) POLBHSD11B1SOAT1KCNH2GFER
SCHEMBL7818005 0.76 HSD11B1 (0.55) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL7810596 0.76 HSD11B1 (0.55) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL10323975 0.74 MEN1 (0.54) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL23975133 0.72 POLB (0.72) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL5697557 0.72 HSD11B1 (0.51) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL1388689 0.72 HSD11B1 (0.51) MEN1KMT2AHSD11B1
SCHEMBL29975007 0.71 L3MBTL1 (0.56) POLBMEN1MAPTKMT2AHSD11B1
SCHEMBL1997854 0.71 L3MBTL1 (0.56) POLBMEN1MAPTKMT2AHSD11B1
SCHEMBL19850690 0.70 HSD11B1 (0.60) POLBSMN1; SMN2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12042496-B2 Methods related to opioid therapeutics THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-23 — — US claimed
US-12303511-B2 Methods related to opioid therapeutics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-05-20 — — US disclosed
US-20240342180-A1 METHODS RELATED TO OPIOID THERAPEUTICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-10-17 — — US disclosed
US-12042496-B2 Methods related to opioid therapeutics THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-23 — — US disclosed
US-20210338680-A1 METHODS RELATED TO OPIOID THERAPEUTICS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342180-A1 METHODS RELATED TO OPIOID THERAPEUTICS OPRL1, OPRK1, GPR139 POLB 4642/4885SMN1; SMN2 2889/4885MEN1 4873/4885
US-12042496-B2 Methods related to opioid therapeutics OPRL1, OPRK1, GPR139 POLB 4642/4885SMN1; SMN2 2889/4885MEN1 4873/4885
US-20210338680-A1 METHODS RELATED TO OPIOID THERAPEUTICS OPRL1, OPRK1, GPR139 POLB 4642/4885SMN1; SMN2 2889/4885MEN1 4873/4885
US-12303511-B2 Methods related to opioid therapeutics OPRL1, OPRK1, GPR139 POLB 4642/4885SMN1; SMN2 2889/4885MEN1 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.